The U.S. pot sector could see an influx of medical research funding from healthcare investors amid renewed interest from pharmaceutical firms, should a proposal to reclassify cannabis as a lower-risk substance be approved, industry experts said. The current classification as a Schedule I substance has limited research into cannabis due to restricted access to cannabis products, regulatory hurdles and funding limitations. Federal research grants are essentially off the table, while... Read this story
